van Praag H M, Kahn R, Asnis G M, Lemus C Z, Brown S L
Biol Psychiatry. 1987 Feb;22(2):205-12. doi: 10.1016/0006-3223(87)90232-0.
The original antidepressants, tricyclics and MAO inhibitors, increase the availability in the brain of both 5-HT and NA. Prompted by clinical findings suggestive of 5-HT disturbances in depression, drugs were developed that increase 5-HT selectively. Data are presented that suggest that broad-spectrum compounds may provide better conditions for antidepressant effects than the 5-HT-selective ones. The hypothesis is proposed that 5-HT potentiators are partial antidepressants, in that they predominantly reduce the anxiety/aggressive component of the depressive syndrome, and deserve to be tested in conditions with heightened anxiety and/or aggression irrespective of the nosological diagnosis. Tentative evidence relates diminished 5-HT metabolism to disordered impulse control. Based on these data, trials of 5-HT potentiators in impulse control disorders unrelated to aggressive drives seem warranted.
最初的抗抑郁药，即三环类药物和单胺氧化酶抑制剂，可提高大脑中5-羟色胺（5-HT）和去甲肾上腺素（NA）的可用性。受抑郁症中提示5-HT紊乱的临床发现的启发，人们开发出了能选择性提高5-HT水平的药物。现有数据表明，与5-HT选择性药物相比，广谱化合物可能为抗抑郁作用提供更好的条件。有人提出这样的假说：5-HT增强剂是部分抗抑郁药，因为它们主要减轻抑郁综合征的焦虑/攻击性成分，并且无论疾病诊断如何，都值得在焦虑和/或攻击性增强的情况下进行测试。初步证据表明5-HT代谢减少与冲动控制紊乱有关。基于这些数据，在与攻击驱力无关的冲动控制障碍中试用5-HT增强剂似乎是有必要的。
